Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Zelira Therapeutics ( (AU:ZLD) ).
Zelira Therapeutics has secured definitive agreements for a transformative US$32.98 million capital raise into its HOPE® 1 special purpose vehicle (SPV), led by TGC Biotechnology Fund (ThirdGate Capital), valuing the SPV at roughly US$66 million post-money and Zelira’s fully diluted stake at about US$26.2 million, or 39.7%. The funding, alongside a A$1.07 million cash refund from Australia’s R&D Tax Incentive Scheme, will support an accelerated U.S. regulatory push for HOPE® 1, including an Investigational New Drug (IND) submission, initiation of a Phase 1 clinical trial—the first formal FDA-regulated dosing of HOPE® 1 in humans—and a planned Orphan Drug Designation filing, positioning the company to potentially unlock regulatory and commercial advantages in the autism treatment market while reinforcing its capital base and strategic relationship with institutional investors.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.66 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a global biopharmaceutical company focused on the development and commercialisation of clinically validated cannabinoid-based medicines. The company’s lead programs include HOPE®, a cannabinoid-derived therapy targeting autism spectrum disorders, with a regulatory and market strategy centered on the U.S. via the FDA’s 505(b)(2) pathway.
Average Trading Volume: 48,970
Technical Sentiment Signal: Buy
Current Market Cap: A$8.63M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.